December 14, 2022
Takeda Pharmaceutical is acquiring NDI-034858, an investigational immune therapy, from US biotech Nimbus Therapeutics for US$4 billion upfront, the Japanese drug juggernaut said on December 13. The company has agreed with Nimbus to purchase the drug through the acquisition of...read more